Bacillus Calmette-Guérin Is Superior to a Combination of Epirubicin and Interferon-α2b in the Intravesical Treatment of Patients with Stage T1 Urinary Bladder Cancer. A Prospective, Randomized, Nordic Study

European Urology

Volumn 57, Issue 1, 2010, Pages 25-31

  Duchek, Miloš ^a   Johansson, Robert ^a   Jahnson, Staffan ^b   Mestad, Oddvar ^c   Hellström, Pekka ^d   Hellsten, Sverker ^e   Malmström, Per Uno ^f  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

^d OULU UNIVERSITY HOSPITAL   (Finland)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bladder cancer; Endovesical adjuvant therapy; Prospective randomized trial

Indexed keywords

BCG VACCINE; EPIRUBICIN; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER SIZE; CARCINOMA IN SITU; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTECTOMY; DISEASE FREE SURVIVAL; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT CANCER; SECOND LOOK SURGERY; URINARY TRACT DISEASE;

ADMINISTRATION, INTRAVESICAL; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCG VACCINE; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; HUMANS; INTERFERON ALFA-2B; KAPLAN-MEIERS ESTIMATE; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SCANDINAVIA; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; URINARY BLADDER NEOPLASMS;

EID: 70449530500     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.09.038     Document Type: Article

References (13)

1. Raitanen M.P., Lukkarinen O., and Finnish Multicentre Study Group. A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Br J Urol 76 (1995) 697-701
2. Babjuk M., Oosterlinck W., Sylvester R., Kaasinen E., Böhle A., and Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54 (2008) 303-314
3. Divrik R.T., Yildirim U., Zorlu F., and Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 175 (2006) 1641-1644
4. Gardmark T., Bladstrom A., Hellsten S., Malmstrom P.U., and members of the Swedish National Bladder Cancer Registry. Analysis of clinical characteristics, management and survival of patients with Ta T1 bladder tumours in Sweden between 1997 and 2001. Scand J Urol Nephrol 40 (2006) 276-282
5. Malmström P.U., Wijkström H., Lundholm C.L., Busch C., Wester K., and Norlén B.J. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 161 (1999) 1124-1127
6. Sylvester R.J., van der Meijden A.P.M., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta-T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477
7. Herr H.W. Is maintenance bacillus Calmette-Guérin really necessary?. Eur Urol 54 (2008) 971-973
8. Gårdmark T., Jahnson S., Wahlquist R., Wijkstrom H., and Malmström P.U. Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guerin in patients with high-risk bladder cancer. BJU Int 99 (2007) 817-820
9. Nieder A.M., Brausi M., Lamm D., et al. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 66 Suppl 1 (2005) 108-125
10. Fernandez-Gomez J., Solsona E., Unda M., et al., Club Urológico Español de Tratamiento Oncológico (CUETO). Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 53 (2008) 992-1002
11. Malmström P.-U., Sylvester R.J., Crawford D.E., et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 56 (2009) 247-256
12. Kaasinen E., Wijkström H., Malmström P.-U., et al., Nordic Urothelial Cancer Group. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study. Eur Urol 43 (2003) 637-645
13. Joudi F.N., Smith B.J., O'Donnell M.A., and National BCG-Interferon Phase 2 Investigator Group. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24 (2006) 344-348